Исследования психоделиков для улучшения жизни умираюших - и здоровых
http://www.newyorker.com/magazine/2015/02/09/trip-treatment?utm_source=tny&utm_medium=email&utm_campaign=dailyemail&mbid=nl_020215_Daily&CNDID=21831230&spMailingID=7470134&spUserID=MjUyNDM5MzI0NTgS1&spJobID=620190617&spReportId=NjIwMTkwNjE3S0
The Trip Treatment (Michael Pollan).
The effects of psilocybin (грибы) resemble those of LSD, but, as one researcher explained, “it carries none of the political and cultural baggage of those three letters.” LSD is also stronger and longer-lasting in its effects, and is considered more likely to produce adverse reactions. Researchers are using or planning to use psilocybin not only to treat anxiety, addiction (to smoking and alcohol), and depression but also to study the neurobiology of mystical experience, which the drug, at high doses, can reliably occasion. Forty years after the Nixon Administration effectively shut down most psychedelic research, the government is gingerly allowing a small number of scientists to resume working with these powerful and still somewhat mysterious molecules.
...
[In 1996] Esalen group had decided on a plan: “to get aboveboard, unassailable research done, at an institution with investigators beyond reproach,” and, ideally, “do this without any promise of clinical treatment.” Jesse was ultimately less interested in people’s mental disorders than in their spiritual well-being-in using entheogens for what he calls “the betterment of well people.”
А вот, оказывается, есть http://www.maps.org/ - Мультидисциплинарная Ассоциация для Психоделических Исследований.
Прямо в ближайший понедельник 9 января начинают первый за 40 лет clinical trail - психоделики для лечения пост-травматического синдрома. В Канаде.
First Clinical Psychedelic Therapy
Trial in Canada in Over 40 Years
Canadian MDMA-Assisted Psychotherapy for
PTSD Study Starts After 8-Year Effort
January 9, 2015
Такие дела, Миша.
The Trip Treatment (Michael Pollan).
The effects of psilocybin (грибы) resemble those of LSD, but, as one researcher explained, “it carries none of the political and cultural baggage of those three letters.” LSD is also stronger and longer-lasting in its effects, and is considered more likely to produce adverse reactions. Researchers are using or planning to use psilocybin not only to treat anxiety, addiction (to smoking and alcohol), and depression but also to study the neurobiology of mystical experience, which the drug, at high doses, can reliably occasion. Forty years after the Nixon Administration effectively shut down most psychedelic research, the government is gingerly allowing a small number of scientists to resume working with these powerful and still somewhat mysterious molecules.
...
[In 1996] Esalen group had decided on a plan: “to get aboveboard, unassailable research done, at an institution with investigators beyond reproach,” and, ideally, “do this without any promise of clinical treatment.” Jesse was ultimately less interested in people’s mental disorders than in their spiritual well-being-in using entheogens for what he calls “the betterment of well people.”
А вот, оказывается, есть http://www.maps.org/ - Мультидисциплинарная Ассоциация для Психоделических Исследований.
Прямо в ближайший понедельник 9 января начинают первый за 40 лет clinical trail - психоделики для лечения пост-травматического синдрома. В Канаде.
First Clinical Psychedelic Therapy
Trial in Canada in Over 40 Years
Canadian MDMA-Assisted Psychotherapy for
PTSD Study Starts After 8-Year Effort
January 9, 2015
Такие дела, Миша.